

DuPont de Nemours, Inc. ("DuPont" or the "Company")
Reconciliation of non-GAAP financial measures and other supplemental information

Unless otherwise indicated, all financial metrics presented reflect continuing operations only.

This communication includes information that does not conform to accounting principles generally accepted in the United States of America ("U.S. GAAP") and are considered non-GAAP measures. Management uses these measures internally for planning, forecasting and evaluating the performance of the Company, including allocating resources. DuPont's management believes these non-GAAP financial measures are useful to investors because they provide additional information related to the ongoing performance of DuPont to offer a more meaningful comparison related to future results of operations. These non-GAAP financial measures supplement disclosures prepared in accordance with U.S. GAAP, and should not be viewed as an alternative to U.S. GAAP. Furthermore, such non-GAAP measures may not be consistent with similar measures provided or used by other companies. Reconciliations for these non-GAAP measures to U.S. GAAP are provided in the following tables. Non-GAAP measures included in this communication are defined below. The Company has not provided forward-looking U.S. GAAP financial measures or a reconciliation of forward-looking non-GAAP financial measures to the most comparable U.S. GAAP financial measures on a forward-looking basis because the Company is unable to predict with reasonable certainty the ultimate outcome of certain future events. These events include, among others, the impact of portfolio changes, including asset sales, mergers, acquisitions, and divestitures; contingent liabilities related to litigation, environmental and indemnifications matters; impairments and discrete tax items. These items are uncertain, depend on various factors, and could have a material impact on U.S. GAAP results for the guidance period.

Indirect costs, such as those related to corporate and shared service functions previously allocated to the Delrin® Divestiture, do not meet the criteria for discontinued operations and were reported within continuing operations in the respective prior periods. A portion of these historical indirect costs include costs related to activities the Company is undertaking on behalf of Delrin® and for which it is reimbursed ("Future Reimbursable Indirect Costs"). Future Reimbursable Indirect Costs are reported within continuing operations but are excluded from operating EBITDA as defined below. The remaining portion of these indirect costs is not subject to future reimbursement ("Stranded Costs"). Stranded Costs are reported within continuing operations in Corporate & Other and are included within Operating EBITDA.

Adjusted Earnings is defined as income from continuing operations excluding the after-tax impact of significant items, after-tax impact of amortization expense of intangibles, the after-tax impact of non-operating pension / other post employment benefits ("OPEB") credits / costs and Future Reimbursable Indirect Costs. Adjusted Earnings is the numerator used in the calculation of Adjusted EPS, as well as the denominator in Adjusted Free Cash Flow Conversion.

Adjusted EPS is defined as Adjusted Earnings per common share - diluted. Management estimates amortization expense in 2025 associated with intangibles to be about \$590 million on a pre-tax basis, or approximately \$1.08 per share.

The Company's measure of profit/loss for segment reporting purposes is Operating EBITDA as this is the manner in which the Company's chief operating decision maker ("CODM") assesses performance and allocates resources. The Company defines Operating EBITDA as earnings (i.e., "Income from continuing operations before income taxes") before interest, depreciation, amortization, non-operating pension / OPEB benefits / charges, and foreign exchange gains / losses, excluding Future Reimbursable Indirect Costs, and adjusted for significant items. Reconciliations of these measures are provided on the following pages.

Operating EBITDA Margin is defined as Operating EBITDA divided by Net Sales.

Incremental Margin is the change in Operating EBITDA divided by the change in Net Sales for the applicable period.

Significant items are items that arise outside the ordinary course of business for the Company, and beginning in the first quarter 2025, includes items for nonconsolidated affiliates, that the Company's management believes may cause misinterpretation of underlying business and investment performance, both historical and future, based on a combination of some or all of the item's size, unusual nature and infrequent occurrence. Management classifies as significant items certain costs and expenses associated with integration and separation activities related to transformational acquisitions and divestitures as they are considered unrelated to ongoing business performance. Management believes the update to the definition of significant items to include those related to nonconsolidated affiliates reflects a more accurate measure of the ongoing performance of the investment. There were no significant items associated with nonconsolidated affiliates recorded for the three-month periods ended March 31, 2025 and March 31, 2024.

Organic Sales is defined as net sales excluding the impacts of currency and portfolio.

Adjusted Free Cash Flow is defined as cash provided by/used for operating activities from continuing operations less capital expenditures and excluding the impact of cash inflows/outflows that are unusual in nature and/or infrequent in occurrence that neither relate to the ordinary course of the Company's business nor reflect the Company's underlying business liquidity. As a result, Adjusted Free Cash Flow represents cash that is available to the Company, after investing in its asset base, to fund obligations using the Company's primary source of liquidity, cash provided by operating activities from continuing operations. Management believes Adjusted Free Cash Flow, even though it may be defined differently from other companies, is useful to investors, analysts and others to evaluate the Company's cash flow and financial performance, and it is an integral measure used in the Company's financial planning process. Management notes that there were no exclusions for items that are unusual in nature and/or infrequent in occurrence for the three-month period ended March 31, 2025.

Adjusted Free Cash Flow Conversion is defined as Adjusted Free Cash Flow divided by Adjusted Earnings. Management uses Adjusted Free Cash Flow Conversion as an indicator of our ability to convert earnings to cash.

Management believes supplemental non-GAAP financial measures including Transaction-Adjusted Free Cash Flow and Transaction-Adjusted Free Cash Flow Conversion (each defined below) provide an integral view of information on the Company's underlying business performance during this period of transformational change. Management believes the Intended Electronics Separation represents a significant transformational change for the Company and the impact of separation-related transaction cost payments are expected to be material to the Company's financial statements. Management believes Transaction-Adjusted Free Cash Flow, which may be defined differently from other companies, is useful to investors, analysts and others to evaluate the Company's cash flow and financial performance, and it is an integral measure used in the Company's financial planning process. These non-GAAP financial measures are not intended to represent residual cash flow for discretionary expenditures since other non-discretionary expenditures, such as mandatory debt service requirements, are not deducted from the measure.

Transaction-Adjusted Free Cash Flow is defined as cash provided by/used for operating activities from continuing operations less capital expenditures, separation-related transaction cost payments and excluding the impact of cash inflows/outflows that are unusual in nature and/or infrequent in occurrence that neither relate to the ordinary course of the Company's business nor reflect the Company's underlying business liquidity.

Transaction-Adjusted Free Cash Flow Conversion is defined as Adjusted Free Cash Flow excluding separation-related transaction costs divided by Adjusted Earnings.

DuPont de Nemours, Inc.

Net Sales

<i>In millions</i>	1Q25	FY 2024	4Q24	3Q24	2Q24	1Q24	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Net Sales	\$ 3,066	\$ 12,386	\$ 3,092	\$ 3,192	\$ 3,171	\$ 2,931	\$ 12,068	\$ 13,017	\$ 12,566	\$ 11,128	\$ 11,703

Selected Non-GAAP Calculation of Operating EBITDA (Unaudited)

<i>In millions</i>	1Q25	FY 2024	4Q24	3Q24	2Q24	1Q24	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
(Loss) income from continuing operations, net of tax (GAAP)	\$ (548)	\$ 778	\$ (61)	\$ 480	\$ 176	\$ 183	\$ 533	\$ 1,061	\$ 1,207	\$ (1,349)	\$ (592)
+ Provision for (benefit from) income taxes on continuing operations	119	414	104	106	120	84	(29)	387	237	90	(103)
(Loss) income from continuing operations before income taxes	\$ (429)	\$ 1,192	\$ 43	\$ 586	\$ 296	\$ 267	\$ 504	\$ 1,448	\$ 1,444	\$ (1,259)	\$ (695)
+ Depreciation and amortization	293	1,194	299	306	298	291	1,147	1,135	1,112	1,086	1,118
- Interest income ¹	18	73	18	14	21	20	155	50	12	18	62
+ Interest expense ²	82	364	83	86	99	96	396	486	503	672	696
- Non-operating pension/OPEB benefit credits (costs)	3	18	4	4	3	7	(9)	28	30	12	56
- Foreign exchange (losses) gains, net	(3)	3	22	(19)	(4)	4	(73)	15	(53)	(54)	(103)
+ Future reimbursable indirect costs	-	-	-	-	-	-	7	52	60	59	59
+ Costs historically allocated to the materials science and agriculture businesses ³	-	-	-	-	-	-	-	-	-	-	256
- Adjustments for significant items (charge) benefit	(860)	(488)	(426)	122	(125)	(59)	(961)	(233)	(22)	(2,260)	(1,801)
Operating EBITDA (non-GAAP)	\$ 788	\$ 3,144	\$ 807	\$ 857	\$ 798	\$ 682	\$ 2,942	\$ 3,261	\$ 3,152	\$ 2,842	\$ 3,220

1. Excludes accrued interest income earned on employee retention credits. Refer to details of significant items on the following page.

2. Excludes interest rate swap basis amortization. Refer to details of significant items on the following page.

3. Costs previously allocated to the materials science and agriculture businesses that did not meet the definition of expenses related to discontinued operations in accordance with ASC 205.

GAAP Income from Continuing Operations Margin

<i>In millions</i>	1Q25	FY 2024	4Q24	3Q24	2Q24	1Q24	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
(Loss) income from continuing operations margin	-17.9%	6.3%	-2.0%	15.0%	5.6%	6.2%	4.4%	8.2%	9.6%	-12.1%	-5.1%

Operating EBITDA Margin

<i>In millions</i>	1Q25	FY 2024	4Q24	3Q24	2Q24	1Q24	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Total operating EBITDA margin (non-GAAP) ¹	25.7%	25.4%	26.1%	26.8%	25.2%	23.3%	24.4%	25.1%	25.1%	25.5%	27.5%

1. Operating EBITDA Margin is Operating EBITDA as a percentage of net sales.

Pretax Significant Items (Unaudited)

<i>In millions</i>	1Q25	FY 2024	4Q24	3Q24	2Q24	1Q24	FY 2023	FY 2022	FY 2021	FY 2020
Acquisition, integration and separation costs ¹	\$ (125)	\$ (168)	\$ (117)	\$ (43)	\$ (5)	\$ (3)	\$ (20)	\$ (193)	\$ (81)	\$ (177)
Restructuring and asset-related charges - net ²	(47)	(87)	(19)	(21)	(8)	(39)	(146)	(61)	(50)	(172)
Goodwill impairment charge ³	(768)	-	-	-	-	-	(804)	-	-	(1,862)
Asset impairment charge ⁴	-	-	-	-	-	-	-	(94)	-	(642)
Net gain on divestitures and changes in joint venture ownership	-	-	-	-	-	-	9	69	143	593
Terminated Intended Rogers acquisition financing fees	-	-	-	-	-	-	-	(6)	(22)	-
Income tax related item ⁵	-	8	-	-	-	8	-	-	-	-
Employee Retention Credit ⁶	3	-	-	-	-	-	-	52	-	-
Inventory write-offs ⁷	-	(25)	1	(2)	1	(25)	-	-	-	-
Loss on debt extinguishment ⁸	-	(74)	-	-	(74)	-	-	-	-	-
Interest rate swap mark-to-market gain (loss) ⁹	78	(138)	(290)	191	(39)	-	-	-	-	-
Interest rate swap amortization ¹⁰	(1)	(2)	(1)	(1)	-	-	-	-	-	-
Inventory step-up amortization ¹¹	-	(2)	-	(2)	-	-	-	-	(12)	-
Total pretax significant items (charge) benefit	\$ (860)	\$ (488)	\$ (426)	\$ 122	\$ (125)	\$ (59)	\$ (961)	\$ (233)	\$ (22)	\$ (2,260)

1. Acquisition, integration and separation costs related to the Previously Intended Business Separations, Intended Electronics Separation, the acquisitions of Donatelle Plastics and Spectrum Plastics Group, the sale of divested business units, and the Terminated Intended Rogers acquisition, which includes a termination fee of \$126 million incurred in the fourth quarter of 2022.

2. Includes restructuring actions and asset related charges.

3. Reflects non-cash goodwill impairment charges in the Aramids reporting unit in the first quarter of 2025, goodwill impairment charge in the former Protection reporting unit (which is now split among the Healthcare, Aramids and Shelter reporting units) in the fourth quarter of 2023 and other goodwill charges in fiscal year 2020.

4. Includes an impairment charge related to an equity method investment that occurred in the first quarter of 2022, and an asset impairment charge within the Retained Businesses in FY 2020.

5. Reflects the impact of an international tax audit.

6. Accrued interest earned on employee retention credits reflected in "Interest income" within "Sundry income(expense) - net" in the first quarter of 2025. Employee Retention Credit pursuant to the Coronavirus Aid, Relief, and Economic Security ("CARES"). as enhanced by the Consolidated Appropriations Act ("CAA") and American Rescue Plan Act ("ARPA") reflected in "Cost of sales," "Research and development expenses" and "Selling, general and administrative expenses" in fiscal year 2022.

7. Reflects net raw material inventory write-offs recorded in "Cost of Sales" in connection with restructuring actions related to plant line closures within the Water & Protection segment.

8. Reflects the loss on extinguishment of debt related to the partial redemption of the 2038 Notes.

9. Includes the net-cash mark-to-market gain (loss) related to the 2022 Swaps and 2024 Swaps and net interest settlement loss related to the 2022 Swaps.

10. Reflects the basis amortization on the 2022 Swaps.

11. Reflects the 2024 amortization of an inventory step-up adjustment related to the Donatelle Plastics acquisition, and the 2021 amortization of an inventory step-up adjustment related to the Laird PM acquisition reflected in cost of sales.

Significant Items, net of tax (Unaudited)

<i>In millions</i>	1Q25	FY 2024	4Q24	3Q24	2Q24	1Q24	FY 2023	FY 2022	FY 2021	FY 2020
Acquisition, integration and separation costs ¹	\$ (106)	\$ (144)	\$ (100)	\$ (38)	\$ (4)	\$ (2)	\$ (18)	\$ (150)	\$ (72)	\$ (150)
Restructuring and asset-related charges - net ²	(37)	(65)	(15)	(16)	(5)	(29)	(111)	(47)	(38)	(130)
Goodwill impairment charge ³	(768)	-	-	-	-	-	(804)	-	-	(1,862)
Asset impairment charge ⁴	-	-	-	-	-	-	-	(65)	-	(490)
Net gain on divestitures and changes in joint venture ownership	-	-	-	-	-	-	7	61	71	338
Terminated Intended Rogers acquisition financing fees	-	-	-	-	-	-	-	(5)	(16)	-
Income tax related item ⁵	(27)	(131)	(102)	-	(29)	-	329	(52)	55	128
Employee Retention Credit ⁶	3	-	-	-	-	-	-	40	-	-
Inventory write-offs ⁷	-	(19)	1	(1)	-	(19)	-	-	-	-
Loss on debt extinguishment ⁸	-	(57)	-	-	(57)	-	-	-	-	-
Interest rate swap mark-to-market gain (loss) ⁹	60	(106)	(224)	148	(30)	-	-	-	-	-
Interest rate swap amortization ¹⁰	-	(1)	-	(1)	-	-	-	-	-	-
Inventory step-up amortization ¹¹	-	(1)	-	(1)	-	-	-	-	(10)	-
Total pretax significant items (charge) benefit, net of tax	\$ (875)	\$ (524)	\$ (440)	\$ 91	\$ (125)	\$ (50)	\$ (597)	\$ (218)	\$ (10)	\$ (2,166)

1. Acquisition, integration and separation costs related to the Previously Intended Business Separations, Intended Electronics Separation, the acquisitions of Donatelle Plastics and Spectrum Plastics Group, the sale of divested business units, and the Terminated Intended Rogers acquisition, which includes a termination fee of \$126 million incurred in the fourth quarter of 2022.

2. Includes restructuring actions and asset related charges.

3. Reflects non-cash goodwill impairment charges in the Aramids reporting unit in Q1 2025, goodwill impairment charge in the former Protection reporting unit (which is now split among the Healthcare, Aramids and Shelter reporting units) in Q4 2023 and other goodwill charges in FY 2020.

4. Includes an impairment charge related to an equity method investment that occurred in the first quarter of 2022, and an asset impairment charge within the Retained Businesses in FY 2020.

5. Reflects the income tax impact of certain internal restructurings related related to the Intended Electronics Separation in Q1 2025, impact of an international tax audit in Q1 and Q2 2024 and the global income tax impacts of internal restructuring involving certain foreign subsidiaries in Q4 2024 and FY 2023.

6. Accrued interest earned on employee retention credits reflected in "Interest income" within "Sundry income(expense) - net" in the first quarter of 2025. Employee Retention Credit pursuant to the Coronavirus Aid, Relief, and Economic Security ("CARES"). as enhanced by the Consolidated Appropriations Act ("CAA") and American Rescue Plan Act ("ARPA") reflected in "Cost of sales," "Research and development expenses" and "Selling, general and administrative expenses" in fiscal year 2022.

7. Reflects net raw material inventory write-offs recorded in "Cost of Sales" in connection with restructuring actions related to plant line closures within the Water & Protection segment.

8. Reflects the loss on extinguishment of debt related to the partial redemption of the 2038 Notes.

9. Includes the mark-to-market gain (loss) related to the 2022 Swaps and 2024 Swaps and net interest settlement loss related to the 2022 Swaps.

10. Reflects the basis amortization on the 2022 Swaps.

11. Reflects the 2024 amortization of an inventory step-up adjustment related to the Donatelle Plastics acquisition, and the 2021 amortization of an inventory step-up adjustment related to the Laird PM acquisition reflected in cost of sales.

Significant Items Earnings Per Share (Unaudited)

<i>In millions</i>	1Q25	FY 2024 ¹	4Q24	3Q24	2Q24	1Q24	FY 2023 ¹	FY 2022 ¹	FY 2021 ¹	FY 2020 ¹
Acquisition, integration and separation costs ²	\$ (0.25)	\$ (0.34)	\$ (0.24)	\$ (0.09)	\$ (0.01)	\$ -	\$ (0.04)	\$ (0.30)	\$ (0.13)	\$ (0.20)
Restructuring and asset-related charges - net ³	(0.09)	(0.15)	(0.03)	(0.04)	(0.01)	(0.07)	(0.25)	(0.09)	(0.07)	(0.18)
Goodwill impairment charge ⁴	(1.83)	-	-	-	-	-	(1.78)	-	-	(2.52)
Asset impairment charge ⁵	-	-	-	-	-	-	-	(0.13)	-	(0.67)
Net gain on divestitures and changes in joint venture ownership	-	-	-	-	-	-	0.02	0.12	0.13	0.46
Terminated Intended Rogers acquisition financing fees	-	-	-	-	-	-	-	(0.01)	(0.03)	-
Income tax related item ⁶	(0.06)	(0.31)	(0.24)	-	(0.07)	-	0.73	(0.11)	0.10	0.17
Employee Retention Credit ⁷	-	-	-	-	-	-	-	0.08	-	-
Inventory write-offs ⁸	-	(0.05)	-	-	-	(0.05)	-	-	-	-
Loss on debt extinguishment ⁹	-	(0.14)	-	-	(0.14)	-	-	-	-	-
Interest rate swap mark-to-market gain (loss) ¹⁰	0.14	(0.26)	(0.53)	0.35	(0.07)	-	-	-	-	-
Interest rate swap amortization ¹¹	-	-	-	-	-	-	-	-	-	-
Inventory step-up amortization ¹²	-	-	-	-	-	-	-	-	(0.02)	-
Total significant items (charge) benefit - diluted	\$ (2.09)	\$ (1.25)	\$ (1.04)	\$ 0.22	\$ (0.30)	\$ (0.12)	\$ (1.32)	\$ (0.44)	\$ (0.02)	\$ (2.94)

1. Earnings (Loss) per share amounts from continuing operations - diluted for the year may not equal the sum of the quarterly (loss) earnings per common share from continuing operations - diluted amounts due to the change in average share calculations.

2. Acquisition, integration and separation costs related to the Previously Intended Business Separations, Intended Electronics Separation, the acquisitions of Donatelle Plastics and Spectrum Plastics Group, the sale of divested business units, and the Terminated Intended Rogers acquisition, which includes a termination fee of \$126 million incurred in the fourth quarter of 2022.

3. Includes restructuring actions and asset related charges.

4. Reflects non-cash goodwill impairment charges in the Aramids reporting unit in Q1 2025, goodwill impairment charge in the former Protection reporting unit (which is now split among the Healthcare, Aramids and Shelter reporting units) in Q4 2023 and other goodwill charges in FY 2020.

5. Includes an impairment charge related to an equity method investment that occurred in the first quarter of 2022, and an asset impairment charge within the Retained Businesses in FY 2020.

6. Reflects the income tax impact of certain internal restructurings related related to the Intended Electronics Separation in Q1 2025, impact of an international tax audit in Q1 and Q2 2024 and the global income tax impacts of internal restructuring involving certain foreign subsidiaries in Q4 2024 and FY 2023.

7. Accrued interest earned on employee retention credits reflected in "Interest income" within "Sundry income(expense) - net" in the first quarter of 2025. Employee Retention Credit pursuant to the Coronavirus Aid, Relief, and Economic Security ("CARES"). as enhanced by the Consolidated Appropriations Act ("CAA") and American Rescue Plan Act ("ARPA") reflected in "Cost of sales," "Research and development expenses" and "Selling, general and administrative expenses" in fiscal year 2022.

8. Reflects net raw material inventory write-offs recorded in "Cost of Sales" in connection with restructuring actions related to plant line closures within the Water & Protection segment.

9. Reflects the loss on extinguishment of debt related to the partial redemption of the 2038 Notes.

10. Includes the mark-to-market gain (loss) related to the 2022 Swaps and 2024 Swaps and net interest settlement loss related to the 2022 Swaps.

11. Reflects the basis amortization on the 2022 Swaps.

12. Reflects the 2024 amortization of an inventory step-up adjustment related to the Donatelle Plastics acquisition, and the 2021 amortization of an inventory step-up adjustment related to the Laird PM acquisition reflected in cost of sales.

DuPont de Nemours, Inc.
Adjusted EPS

Pretax Non-GAAP Adjustments to Net Income (Unaudited)

<i>In millions</i>	1Q25	FY 2024	4Q24	3Q24	2Q24	1Q24	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
(Loss) income from continuing operations before income taxes (GAAP)	\$ (429)	\$ 1,192	\$ 43	\$ 586	\$ 296	\$ 267	\$ 504	\$ 1,448	\$ 1,444	\$ (1,259)	\$ (695)
Less: Significant items (charge) benefit, before tax ¹	(860)	(488)	(426)	122	(125)	(59)	(961)	(233)	(22)	(2,260)	(1,801)
Less: Amortization of intangibles, before tax ¹	(146)	(595)	(146)	(149)	(151)	(149)	(600)	(590)	(566)	(542)	(545)
Less: Non-op pension / OPEB benefit credits (costs), before tax ¹	3	18	4	4	3	7	(9)	28	30	12	56
Less: Future reimbursable indirect costs, before tax ¹	-	-	-	-	-	-	(7)	(52)	(60)	(59)	(59)
Less: Costs historically allocated to the materials science and agriculture businesses, before tax ¹	-	-	-	-	-	-	-	-	-	-	(256)
Adjusted earnings, before tax (non-GAAP)	\$ 574	\$ 2,257	\$ 611	\$ 609	\$ 569	\$ 468	\$ 2,081	\$ 2,295	\$ 2,062	\$ 1,590	\$ 1,910

1. Impact on income (loss) from continuing operations before income taxes.

Non-GAAP Adjustments to Net Income (Unaudited)

<i>In millions</i>	1Q25	FY 2024	4Q24	3Q24	2Q24	1Q24	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Net (loss) income from continuing operations available to DuPont common stockholders (GAAP)	\$ (555)	\$ 743	\$ (73)	\$ 472	\$ 169	\$ 175	\$ 494	\$ 1,008	\$ 1,177	\$ (1,365)	\$ (612)
Less: Significant items (charge) benefit, net of tax ¹	(875)	(524)	(440)	91	(125)	(50)	(597)	(218)	(10)	(2,166)	(1,449)
Less: Amortization of intangibles, net of tax ¹	(114)	(460)	(113)	(116)	(116)	(115)	(468)	(459)	(441)	(418)	(418)
Less: Non-op pension / OPEB benefit credits (costs), net of tax ¹	2	15	4	3	2	6	(7)	23	18	9	52
Less: Future reimbursable indirect costs, net of tax ¹	-	-	-	-	-	-	(4)	(40)	(46)	(45)	(45)
Less: Costs historically allocated to the materials science and agriculture businesses, before tax ¹	-	-	-	-	-	-	-	-	-	-	(196)
Adjusted earnings, net of tax (non-GAAP)	\$ 432	\$ 1,712	\$ 476	\$ 494	\$ 408	\$ 334	\$ 1,570	\$ 1,702	\$ 1,656	\$ 1,255	\$ 1,444

1. Impact on income (loss) from continuing operations available to DuPont common stockholders, net of tax. The income tax effect for each adjustment was calculated based on the statutory tax rate for the jurisdiction(s) in which the adjustment was taxable or deductible.

Non-GAAP Adjustments to Earnings Per Share (Unaudited)

<i>In millions</i>	1Q25	FY 2024 ¹	4Q24	3Q24	2Q24	1Q24	FY 2023 ¹	FY 2022 ¹	FY 2021 ¹	FY 2020 ¹	FY 2019 ¹
(Loss) earnings per common share from continuing operations - diluted (GAAP)	\$ (1.33)	\$ 1.77	\$ (0.17)	\$ 1.13	\$ 0.40	\$ 0.41	\$ 1.09	\$ 2.02	\$ 2.16	\$ (1.86)	\$ (0.82)
Less: Significant items (charge) benefit - diluted ²	(2.09)	(1.25)	(1.04)	0.22	(0.30)	(0.12)	(1.32)	(0.44)	(0.02)	(2.94)	(1.94)
Less: Amortization of intangibles - diluted ²	(0.27)	(1.09)	(0.27)	(0.28)	(0.28)	(0.27)	(1.04)	(0.92)	(0.81)	(0.57)	(0.56)
Less: Non-op pension / OPEB benefit credits (costs) - diluted ²	-	0.04	0.01	0.01	0.01	0.01	(0.02)	0.05	0.03	0.01	0.07
Less: Future reimbursable indirect costs - diluted ²	-	-	-	-	-	-	(0.01)	(0.08)	(0.08)	(0.07)	(0.06)
Less: Costs historically allocated to the materials science and agriculture businesses, before tax ²	-	-	-	-	-	-	-	-	-	-	(0.26)
Adjusted earnings per common share from continuing operations - diluted (non-GAAP)	\$ 1.03	\$ 4.07	\$ 1.13	\$ 1.18	\$ 0.97	\$ 0.79	\$ 3.48	\$ 3.41	\$ 3.04	\$ 1.71	\$ 1.93

1. Earnings (loss) per share amounts from continuing operations - diluted for the year may not equal the sum of the quarterly earnings (loss) per common share from continuing operations - diluted amounts due to the change in average share calculations.

2. Impact on earnings per common share from continuing operations - diluted.

DuPont de Nemours, Inc.

Supplemental Information - Selected Segment Information (Unaudited)

Net Trade Revenue by Segment and Business or Major Product Line

<i>In millions</i>	1Q25	FY 2024	4Q24	3Q24	2Q24	1Q24	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Semiconductor Technologies ¹	\$ 644	\$ 2,452	\$ 617	\$ 639	\$ 617	\$ 579	\$ 2,251	\$ 2,617	\$ 2,394	\$ 2,018	\$ 1,805
Interconnect Solutions ¹	474	1,884	484	508	487	405	1,783	2,140	2,011	1,621	1,517
ElectronicsCo¹	\$ 1,118	\$ 4,336	\$ 1,101	\$ 1,147	\$ 1,104	\$ 984	\$ 4,034	\$ 4,757	\$ 4,405	\$ 3,639	\$ 3,322
Healthcare & Water Technologies ¹	\$ 764	\$ 2,976	\$ 790	\$ 769	\$ 744	\$ 673	\$ 2,919	\$ 2,835	\$ 2,672	\$ 2,565	\$ 2,184
Diversified Industrials ¹	1,184	5,074	1,201	1,276	1,323	1,274	5,115	5,344	4,993	4,261	5,097
IndustrialsCo¹	\$ 1,948	\$ 8,050	\$ 1,991	\$ 2,045	\$ 2,067	\$ 1,947	\$ 8,034	\$ 8,179	\$ 7,665	\$ 6,826	\$ 7,281
Corporate¹	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 81	\$ 496	\$ 663	\$ 1,100
Total	\$ 3,066	\$ 12,386	\$ 3,092	\$ 3,192	\$ 3,171	\$ 2,931	\$ 12,068	\$ 13,017	\$ 12,566	\$ 11,128	\$ 11,703

1. Effective in the first quarter of 2025, in light of the Intended Electronics Separation, the Company realigned its management and reporting structure. This realignment resulted in a change in reportable segments in the first quarter of 2025 which changed the manner in which the Company reports financial results by segment. As a result, commencing with the first quarter of 2025, the businesses to be separated as part of the Intended Electronics Separation, ElectronicsCo, are reported separately from the other businesses of DuPont, IndustrialsCo. The information presented above has been recast for all periods presented to reflect the new two segment reporting structure.

2. Net sales reflected in Corporate includes activity of previously divested businesses.

DuPont de Nemours, Inc.
Segment Information (Unaudited)

Net Sales

<i>In millions</i>	1Q25	FY 2024	4Q24	3Q24	2Q24	1Q24	FY 2023	FY 2022	FY 2021	FY 2020
ElectronicsCo	\$ 1,118	\$ 4,336	\$ 1,101	\$ 1,147	\$ 1,104	\$ 984	\$ 4,034	\$ 4,757	\$ 4,405	\$ 3,639
IndustrialsCo	1,948	8,050	1,991	2,045	2,067	1,947	8,034	8,179	7,665	6,826
Corporate	-	-	-	-	-	-	-	81	496	663
Total net sales by segment	\$ 3,066	\$ 12,386	\$ 3,092	\$ 3,192	\$ 3,171	\$ 2,931	\$ 12,068	\$ 13,017	\$ 12,566	\$ 11,128

Operating EBITDA

<i>In millions</i>	1Q25	FY 2024	4Q24	3Q24	2Q24	1Q24	FY 2023	FY 2022	FY 2021	FY 2020
ElectronicsCo	\$ 373	\$ 1,372	\$ 370	\$ 379	\$ 328	\$ 295	\$ 1,153	\$ 1,529	\$ 1,443	\$ 1,204
IndustrialsCo	464	1,920	481	505	495	439	1,915	1,894	1,821	1,653
Corporate	(49)	(148)	(44)	(27)	(25)	(52)	(126)	(162)	(112)	(15)
Total operating EBITDA (non-GAAP)	\$ 788	\$ 3,144	\$ 807	\$ 857	\$ 798	\$ 682	\$ 2,942	\$ 3,261	\$ 3,152	\$ 2,842

Operating EBITDA Margin

<i>In millions</i>	1Q25	FY 2024	4Q24	3Q24	2Q24	1Q24	FY 2023	FY 2022	FY 2021	FY 2020
ElectronicsCo	33.4%	31.6%	33.6%	33.0%	29.7%	30.0%	28.6%	32.1%	32.8%	33.1%
IndustrialsCo	23.8%	23.9%	24.2%	24.7%	23.9%	22.5%	23.8%	23.2%	23.8%	24.2%
Total operating EBITDA margin (non-GAAP) ^{1,2}	25.7%	25.4%	26.1%	26.8%	25.2%	23.3%	24.4%	25.1%	25.1%	25.5%

1. Operating EBITDA Margin is Operating EBITDA as a percentage of net sales.

2. Operating EBITDA Margin %'s for Corporate are not presented separately above as they are not meaningful; however, the results of Corporate are included in the total operating EBITDA margin %'s above.

Significant Items (Pretax)

<i>In millions</i>	1Q25	FY 2024	4Q24	3Q24	2Q24	1Q24	FY 2023	FY 2022	FY 2021	FY 2020
ElectronicsCo	\$ (5)	\$ (4)	\$ (2)	\$ 2	\$ 4	\$ (8)	\$ (31)	\$ (93)	\$ (21)	\$ 190
IndustrialsCo	(779)	(117)	(21)	(28)	(18)	(50)	(889)	35	(30)	(490)
Corporate	(76)	(367)	(403)	148	(111)	(1)	(41)	(175)	29	(1,960)
Total significant items (charge) benefit by segment (Pretax)	\$ (860)	\$ (488)	\$ (426)	\$ 122	\$ (125)	\$ (59)	\$ (961)	\$ (233)	\$ (22)	\$ (2,260)

Depreciation and Amortization (Pretax)

<i>In millions</i>	1Q25	FY 2024	4Q24	3Q24	2Q24	1Q24	FY 2023	FY 2022	FY 2021	FY 2020
ElectronicsCo	\$ 103	\$ 432	\$ 107	\$ 112	\$ 107	\$ 106	\$ 442	\$ 444	\$ 385	\$ 328
IndustrialsCo	191	767	194	195	192	186	710	671	699	688
Corporate ¹	(1)	(5)	(2)	(1)	(1)	(1)	(5)	20	28	70
Total depreciation and amortization by segment (Pretax)	\$ 293	\$ 1,194	\$ 299	\$ 306	\$ 298	\$ 291	\$ 1,147	\$ 1,135	\$ 1,112	\$ 1,086

1. Corporate primarily reflects impacts of previously divested businesses

Equity Earnings

<i>In millions</i>	1Q25	FY 2024	4Q24	3Q24	2Q24	1Q24	FY 2023	FY 2022	FY 2021	FY 2020
ElectronicsCo	\$ 9	\$ 37	\$ 4	\$ 10	\$ 13	\$ 10	\$ 16	\$ 31	\$ 41	\$ 35
IndustrialsCo	4	30	7	6	8	9	35	39	36	25
Corporate	(14)	(8)	(1)	(2)	2	(7)	-	5	8	108
Total equity earnings included in operating EBITDA (non-GAAP)	\$ (1)	\$ 59	\$ 10	\$ 14	\$ 23	\$ 12	\$ 51	\$ 75	\$ 85	\$ 168

DuPont de Nemours, Inc.

Reconciliation of "Cash provided by operating activities - continuing operations" to Adjusted Free Cash Flow , Transaction-Adjusted Free Cash Flow and calculation of "Adjusted Free Cash Flow Conversion" and "Transaction-Adjusted Free Cash Flow Conversion" (Unaudited)

<i>In millions</i>	1Q25	FY 2024	4Q24	3Q24	2Q24	1Q24	FY 2023	FY 2022	FY 2021
Cash provided by operatng activities (GAAP) - continuing operations	\$ 382	\$ 2,321	\$ 564	\$ 737	\$ 527	\$ 493	\$ 2,191	\$ 1,249	\$ 1,846
Capital expenditures	(249)	(579)	(161)	(109)	(102)	(207)	(619)	(662)	(788)
Rogers termination fee ¹	-	-	-	-	-	-	-	163	-
Adjusted free cash flow (non-GAAP) ²	\$ 133	\$ 1,742	\$ 403	\$ 628	\$ 425	\$ 286	\$ 1,572	\$ 750	\$ 1,058
Separation-related transaction cost payments	79	64	52	12	-	-	-	-	-
Transaction-adjusted free cash flow (non-GAAP) ²	\$ 212	\$ 1,806	\$ 455	\$ 640	\$ 425	\$ 286	\$ 1,572	\$ 750	\$ 1,058
Adjusted earnings (non-GAAP) ³	\$ 432	\$ 1,712	\$ 476	\$ 494	\$ 408	\$ 334	\$ 1,570	\$ 1,702	\$ 1,656
Adjusted free cash flow conversion (non-GAAP) ⁴	31%	102%	85%	127%	104%	86%	100%	44%	64%
Transaction-adjusted free cash flow conversion (non-GAAP) ⁴	49%	105%	96%	130%	104%	86%	100%	44%	64%

1. Represents the termination fee associated with the Terminated Intended Rogers Transaction.

2. Calculated on a continuing operations basis for all periods presented.

3. Refer to the Non-GAAP reconciliation of Net income from continuing operations available for DuPont common stockholders to Adjusted Earnings (Non-GAAP) for further information.

4. Refer to the definitions in the non-GAAP financial measures section for further information.

Cash to Accrual Capital Expenditures (Unaudited) - Continuing Operations

<i>In millions</i>	1Q25	FY 2024	4Q24	3Q24	2Q24	1Q24	FY 2023	FY 2022	FY 2021
Capital Expenditure (GAAP - per cash flow)	\$ 249	\$ 579	\$ 161	\$ 109	\$ 102	\$ 207	\$ 619	\$ 662	\$ 788
Less: Cash to Accrual Adjustment ¹	146	(40)	(114)	(35)	(4)	113	29	(3)	(17)
Purchases of Property, Plant & Equipment (accrual basis)	\$ 103	\$ 619	\$ 275	\$ 144	\$ 106	\$ 94	\$ 590	\$ 665	\$ 805

1. Reflects the incremental cash spent or unpaid on capital expenditures for continuing operations.